Serum S100B protein is associated with depressive symptoms in patients with end-stage renal disease

Clinical Biochemistry

Volumn 45, Issue 18, 2012, Pages 1573-1577

  Kim, Jwa Kyung ^a,b   Kim, Sung Gyun ^a,b   Kim, Hyung Jik ^a,b   Song, Young Rim ^a,b  

^a Hallym University   (South Korea)

^b Hallym University College of Medicine   (South Korea)

Author keywords

Depression; End stage renal disease; Inflammation; S100B

Indexed keywords

C REACTIVE PROTEIN; PROTEIN S100B;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD ANALYSIS; DEPRESSION; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; C-REACTIVE PROTEIN; DEPRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PSYCHIATRIC STATUS RATING SCALES; S100 PROTEINS; YOUNG ADULT;

EID: 84870675605     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.08.014     Document Type: Article

References (25)

1. Cohen S.D., Norris L., Acquaviva K., Peterson R.A., Kimmel P.L. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol 2007, 2:1332-1342.
2. Ibrahim S., El Salamony O. Depression, quality of life and malnutrition-inflammation scores in hemodialysis patients. Am J Nephrol 2008, 28:784-791.
3. Kimmel P.L., Peterson R.A. Depression in patients with end-stage renal disease treated with dialysis: has the time to treat arrived?. Clin J Am Soc Nephrol 2006, 1:349-352.
4. Goncalves C.A., Leite M.C., Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008, 41:755-763.
5. Sorci G., Bianchi R., Riuzzi F., Tubaro C., Arcuri C., Giambanco I., et al. S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond. Cardiovasc Psychiatry Neurol 2010, [Epub 2010 Aug 18].
6. Steiner J., Bogerts B., Schroeter M.L., Bernstein H.G. S100B protein in neurodegenerative disorders. Clin Chem Lab Med 2011, 49:409-424.
7. Bramanti V., Tomassoni D., Avitabile M., Amenta F., Avola R. Biomarkers of glial cell proliferation and differentiation in culture. Front Biosci (Schol Ed) 2010, 2:558-570.
8. Grabe H.J., Ahrens N., Rose H.J., Kessler C., Freyberger H.J. Neurotrophic factor S100 beta in major depression. Neuropsychobiology 2001, 44:88-90.
9. Schroeter M.L., Abdul-Khaliq H., Krebs M., Diefenbacher A., Blasig I.E. Serum markers support disease-specific glial pathology in major depression. J Affect Disord 2008, 111:271-280.
10. Schroeter M.L., Abdul-Khaliq H., Sacher J., Steiner J., Blasig I.E., Mueller K. Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc Psychiatry Neurol 2010, 2010:780645.
11. Schroeter M.L., Abdul-Khaliq H., Diefenbacher A., Blasig I.E. S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 2002, 13:1675-1678.
12. Arolt V., Peters M., Erfurth A., Wiesmann M., Missler U., Rudolf S., et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 2003, 13:235-239.
13. Kleindienst A., Hesse F., Bullock M.R., Buchfelder M. The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog Brain Res 2007, 161:317-325.
14. Rothermundt M., Arolt V., Wiesmann M., Missler U., Peters M., Rudolf S., et al. S-100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 2001, 66:89-93.
15. Jang B.S., Kim H., Lim S.W., Jang K.W., Kim D.K. Serum S100B levels and major depressive disorder: its characteristics and role in antidepressant response. Psychiatry Invest 2008, 5:193-198.
16. Vanholder R., De Smet R., Glorieux G., Argiles A., Baurmeister U., Brunet P., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003, 63:1934-1943.
17. Chilcot J., Norton S., Wellsted D., Almond M., Davenport A., Farrington K. A confirmatory factor analysis of the Beck Depression Inventory-II in end-stage renal disease patients. J Psychosom Res 2011, 71:148-153.
18. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6:219-233.
19. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
20. Blyth B.J., Farhavar A., Gee C., Hawthorn B., He H., Nayak A., et al. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma 2009, 26:1497-1507.
21. Hampel H., Kotter H.U., Moller H.J. Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. Alzheimer Dis Assoc Disord 1997, 11:78-87.
22. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999, 461:25-46.
23. Okuno S., Ishimura E., Kohno K., Fujino-Katoh Y., Maeno Y., Yamakawa T., et al. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant 2009, 24:571-577.
24. Mumtaz A., Anees M., Bilal M., Ibrahim M. Beta-2 microglobulin levels in hemodialysis patients. Saudi J Kidney Dis Transpl 2010, 21:701-706.
25. Cheung A.K., Rocco M.V., Yan G., Leypoldt J.K., Levin N.W., Greene T., et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006, 17:546-555.